查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1703488

口干症治疗市场－全球产业规模、份额、趋势、机会和预测，按类型（OTC、处方药）、按产品（唾液刺激剂、唾液替代品、牙膏）、按地区和竞争情况划分，2020 年至 2030 年预测

Xerostomia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球口干症治疗市场价值为 21.5 亿美元，预计将稳定成长，到 2030 年年复合成长率(CAGR) 为 3.75%。该市场涵盖一系列旨在控制和缓解口干症症状的产品和治疗方法。

市场概览
预测期 2026-2030
2024年市场规模 21.5亿美元
2030年市场规模 26.9亿美元
2025-2030 年复合年增长率 3.75%
成长最快的领域 场外交易
最大的市场 北美洲

口干症是一种以唾液腺功能减弱或缺失为特征的疾病，导致唾液分泌减少。它可能由多种因素引起，包括药物副作用、慢性疾病、放射疗法和自然老化过程。

关键市场驱动因素

人口老化日益加剧

主要市场挑战

认知有限和诊断不足

主要市场趋势

个人化医疗和标靶治疗方法

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：口干症治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依类型（非处方药、处方药）
    • 副产品（唾液刺激剂、唾液替代品、牙膏）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美口干症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲口干症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章：亚太地区口干症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美洲口干症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲口干症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章：全球口干症治疗市场：SWOT 分析

第 14 章：竞争格局

  • GlaxoSmithKline plc
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Hikma Pharmaceuticals PLC
  • Pendopharm
  • Sun Pharmaceuticals Industries Ltd
  • Lupin Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Parnell Pharmaceuticals, Inc.
  • Acacia Pharma.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 16619

Global Xerostomia Therapeutics Market was valued at USD 2.15 billion in 2024 and is expected to register steady growth, projecting a compound annual growth rate (CAGR) of 3.75% through 2030. This market encompasses a range of products and treatments aimed at managing and alleviating the symptoms of xerostomia-commonly referred to as dry mouth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.15 Billion
Market Size 2030USD 2.69 Billion
CAGR 2025-20303.75%
Fastest Growing SegmentOTC
Largest MarketNorth America

Xerostomia is a condition characterized by diminished or absent salivary gland function, resulting in reduced saliva production. It can be caused by a variety of factors, including side effects of medications, chronic illnesses, radiation therapy, and the natural aging process.

Key Market Drivers

Growing Aging Population

The increasing global aging population is a primary driver for the expansion of the xerostomia therapeutics market. By 2050, approximately 80% of the world's elderly population is projected to reside in low- and middle-income countries-marking a substantial demographic shift with far-reaching economic and healthcare implications.

The pace of population aging is accelerating, creating both challenges and new opportunities within the healthcare sector. Notably, in 2020, the global population aged 60 and above exceeded the number of children under the age of five for the first time. Between 2015 and 2050, the proportion of individuals aged 60+ is expected to nearly double from 12% to 22%, emphasizing the urgent need for age-responsive healthcare solutions and infrastructure.

Xerostomia is particularly prevalent among older adults due to age-related decline in salivary gland function, which reduces saliva production. This not only impacts seniors' comfort and quality of life but also increases their susceptibility to oral infections and dental problems. Consequently, the elderly represent a growing and high-priority target group for xerostomia therapeutics.

Prevalence estimates for xerostomia in the general population vary widely, ranging from 0.9% to 64.8%, but the condition is significantly more common among older individuals-affecting approximately 30% of those over 65 and up to 40% of those over 80. In addition, seniors are more likely to be prescribed multiple medications for chronic conditions such as hypertension, diabetes, and cardiovascular disease, many of which list dry mouth as a common side effect. This further increases the incidence of xerostomia in older adults and, in turn, drives demand for effective treatment options to alleviate symptoms and improve adherence to long-term medication regimens.

Key Market Challenges

Limited Awareness and Underdiagnosis

One of the primary challenges facing the xerostomia therapeutics market is the widespread underdiagnosis of the condition. Because dry mouth often appears as a secondary symptom of other diseases or medication use, it is frequently overlooked in clinical settings.

Healthcare professionals may not always recognize xerostomia as a standalone issue, which can delay diagnosis and treatment. Additionally, many individuals experiencing dry mouth are unaware that the condition is medically treatable. Symptoms are often mistaken as normal aspects of aging or expected medication side effects, leading patients to forgo medical consultation. This lack of awareness-both among healthcare providers and the general public-poses a barrier to market growth.

Key Market Trends

Personalized Medicine and Targeted Therapeutic Approaches

A notable trend within the xerostomia therapeutics market is the shift toward personalized medicine. Advances in genomics and molecular science are providing deeper insights into the genetic and biological mechanisms that contribute to xerostomia in individual patients, enabling the development of more precise and effective treatments.

Pharmacogenomics-the study of how genetic variations influence drug response-is becoming increasingly important in tailoring xerostomia therapies. This approach allows clinicians to identify the most suitable treatment options for individual patients, thereby minimizing ineffective treatments and improving outcomes.

Ongoing research is also focused on identifying biomarkers associated with xerostomia, which may facilitate early diagnosis and aid in the selection of optimal treatment strategies. These developments hold significant promise for enhancing therapeutic efficacy and offering more targeted, personalized care to patients suffering from dry mouth.

Key Market Players

  • GlaxoSmithKline plc
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Hikma Pharmaceuticals PLC
  • Pendopharm
  • Sun Pharmaceuticals Industries Ltd
  • Lupin Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Parnell Pharmaceuticals, Inc.
  • Acacia Pharma

Report Scope:

In this report, the Global Xerostomia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xerostomia Therapeutics Market, By Type:

  • OTC
  • Prescription

Xerostomia Therapeutics Market, By Product:

  • Salivary Stimulants
  • Salivary Substitutes
  • Dentifrices

Xerostomia Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Xerostomia Therapeutics Market.

Available Customizations:

Global Xerostomia Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Xerostomia Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (OTC, Prescription)
    • 5.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Xerostomia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Xerostomia Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Xerostomia Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Xerostomia Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product

7. Europe Xerostomia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Xerostomia Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
    • 7.3.2. United Kingdom Xerostomia Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
    • 7.3.3. Italy Xerostomia Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
    • 7.3.4. France Xerostomia Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Xerostomia Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product

8. Asia-Pacific Xerostomia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Xerostomia Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
    • 8.3.2. India Xerostomia Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Xerostomia Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Xerostomia Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Xerostomia Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product

9. South America Xerostomia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Xerostomia Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
    • 9.3.2. Argentina Xerostomia Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
    • 9.3.3. Colombia Xerostomia Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product

10. Middle East and Africa Xerostomia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Xerostomia Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
    • 10.3.2. Saudi Arabia Xerostomia Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
    • 10.3.3. UAE Xerostomia Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Xerostomia Therapeutics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. GlaxoSmithKline plc
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Church & Dwight Co., Inc.
  • 14.3. Colgate-Palmolive Company
  • 14.4. Hikma Pharmaceuticals PLC
  • 14.5. Pendopharm
  • 14.6. Sun Pharmaceuticals Industries Ltd
  • 14.7. Lupin Pharmaceuticals, Inc.
  • 14.8. Pfizer, Inc.
  • 14.9. Parnell Pharmaceuticals, Inc.
  • 14.10.Acacia Pharma.

15. Strategic Recommendations

16. About Us & Disclaimer